Sildenafil
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Sildenafil and local guidelines before prescribing.
PDE5 inhibitor
Mechanism
PDE5 inhibitor enhancing cGMP.
Uses
Erectile dysfunction, pulmonary arterial hypertension.
Dosing
- Sildenafil Pulmonary arterial hypertension (adult) | 20 mg three times daily (specialist). Never with nitrates.
Cardiology: Congenital heart disease › 6.36 Drug Reference Table
Side effects
Headache, flushing, dyspepsia, visual disturbance, hypotension.
Interactions
Nitrates and nicorandil contraindicated; CYP3A4 inhibitors raise levels.
Contraindications and cautions
Nitrates, recent MI or stroke, severe hypotension
Monitoring
BP
Pregnancy and breastfeeding
Not applicable
Renal and hepatic impairment
Reduce dose in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
Avoid in recent MI or stroke, severe hypotension; seek help for priapism.
More from the textbook: uses, cautions and other points
- Contraindicated with PDE5 inhibitors (sildenafil, tadalafil - severe hypotension), severe aortic stenosis, HCM with obstruction, hypotension, RV infarction (preload-dependent).
Cardiology: Anatomy Physiology and Pharmacology - GTN / isosorbide mononitrate | Nitric oxide donors; headache; nitrate-free period; never with sildenafil.
Cardiology: Anatomy Physiology and Pharmacology - Contraindication: Do not give within 24–48 hours of a PDE-5 inhibitor (e.g. sildenafil) because of the risk of profound hypotension.
Cardiology: Ischaemic Heart Disease (ACS) › 1.08 Drug Treatment of Stable Angina - Advanced pulmonary vasodilators: E.g. bosentan (an endothelin receptor antagonist), sildenafil.
Cardiology: Congenital heart disease › 6.30 Eisenmenger Syndrome - Nitric oxide pathway - PDE5 inhibitors (sildenafil, tadalafil - never with nitrates ; headache, flushing); riociguat (soluble guanylate cyclase stimulator - also for CTEPH; don't combine with PDE5 inhibitors).
Respiratory: Anatomy, Physiology and Pharmacology - Sildenafil / bosentan / epoprostenol | Pulmonary arterial hypertension (specialist); no nitrates with sildenafil; bosentan - liver, teratogenic.
Respiratory: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (3 mentions)
- Cardiology: Ischaemic Heart Disease (ACS) (1 mention)
- Cardiology: Congenital heart disease (2 mentions)
- Respiratory: Anatomy, Physiology and Pharmacology (2 mentions)
- Respiratory: Pulmonary Vascular Disease (2 mentions)
- Respiratory: Sleep and Breathing (Complete) (1 mention)
- Endocrinology: Diabetes (1 mention)
- Rheumatology: Connective tissue diseases (3 mentions)
- ENT Anatomy Physiology (1 mention)
- Ophthalmology: Anatomy Physiology and Pharmacology (1 mention)
- Ophthalmology: Retinal Visual Loss (1 mention)
- Ophthalmology: Neuro-ophthalmology (1 mention)
- ID: How Infection Happens (1 mention)
- ID: HIV, viral hepatitis and blood-borne viruses (1 mention)
- Surgery: Vascular surgery (1 mention)
- Surgey: Urology (1 mention)
- Clinical pharmacology and prescribing: Adverse drug reactions, interactions and drug allergy (4 mentions)
- Clinical pharmacology and prescribing: Poisoning and overdose (1 mention)
- Integrated cardiology chapter (3 mentions)
- Integrated respiratory chapter (2 mentions)
- Physiology: Nerve, muscle and autonomic systems, exercise, pregnancy and ageing (1 mention)